Regulus Therapeutics
{{Verification|date=August 2022}}
{{Infobox company
| name = Regulus Therapeutics Inc.
| logo =
| type = Public
| traded_as = {{NASDAQ|RGLS}}
| industry = Biotechnology
| key_people = {{ubl|Jay Hagan (president and CEO)|Cris Calsada (CFO)}}
| products = microRNA therapeutics
| num_employees = 30
| foundation = {{start date and age|2007|09}} (by Alnylam Pharmaceuticals (NASDAQ:ALNY) and Isis Pharmaceuticals (NASDAQ:ISIS))
| location = San Diego, California, U.S.
| homepage = {{url|http://regulusrx.com/}}
}}
Regulus Therapeutics Inc. is a clinical stage biopharmaceutical company focused on the development of first-in-class drugs that target microRNAs to treat a broad range of diseases. Regulus was established in September 2007 by Alnylam Pharmaceuticals and Isis Pharmaceuticals.{{cite web |url=http://www.drugdiscoverynews.com/index.php?newsarticle=5030 |title=Omics & Systems Biology, Surf's Up for microRNAs |publisher=Drug Discovery News |author=Hutton, David |date=June 2011 }} In April 2025, Novartis announced that it had entered into an agreement to acquire Regulus.
microRNA explained
MicroRNAs are small naturally occurring RNA molecules, typically 20 to 25 nucleotides in length, that do not encode proteins but instead have evolved to regulate gene expression.{{cite web |url=http://www.sandiegomagazine.com/media/San-Diego-Magazine/October-2010/The-Miracle-of-microRNA/ |title=The miracle of microRNA |publisher= |work=San Diego Magazine |author=Senese, Mike |date=October 2010 |url-status=dead |archiveurl=https://web.archive.org/web/20111209225535/http://www.sandiegomagazine.com/media/San-Diego-Magazine/October-2010/The-Miracle-of-microRNA/ |archivedate=2011-12-09 }}{{cite web |url=http://www.genengnews.com/gen-articles/mirna-drugs-close-in-on-clinical-debut/3600/ |title=miRNA Drugs Close In on Clinical Debut |publisher= |work=Genetic Engineering & Biotechnology News |author=Liszewski, Kathy |date=May 15, 2011 }}
anti-miR therapeutics
Anti-miR therapeutics inhibit specific microRNA targets. Animal models showed that modulating microRNAs through anti-miRs effectively regulates biological processes and provides therapeutic benefit to cardiac dysfunction, cancer and hepatitis C virus infection. Administration of anti-miR oligonucleotides is possible through local or parenteral injection.{{cite web |url=http://pharmtech.findpharma.com/pharmtech/Drug+Delivery/Perspectives-in-MicroRNA-Therapeutics/ArticleStandard/Article/detail/718858 |archive-url=https://web.archive.org/web/20111007084231/http://pharmtech.findpharma.com/pharmtech/Drug+Delivery/Perspectives-in-MicroRNA-Therapeutics/ArticleStandard/Article/detail/718858 |url-status=dead |archive-date=2011-10-07 |title=Perspectives in MictoRNA Therapeutics |publisher= Pharmaceutical Technology |author1=Steffy, Kevin |author2=Allerson, Charles |author3=Bhat, Balkrishen |date=May 2011 }} The company's lead drug candidate, farabursen (RGLS8429), is in development for autosomal dominant polycystic kidney disease (ADPKD).
Strategic alliances
In April 2008, Regulus and GlaxoSmithKline (GSK) entered into a microRNA-focused strategic alliance for the discovery, development and commercialization of novel microRNA-targeted therapeutics to treat inflammatory diseases such as rheumatoid arthritis. In February 2010, Regulus and GSK announced a new collaboration to develop and commercialize microRNA therapeutics targeting microRNA-122 (miR-122) for the treatment of hepatitis C (HCV) infection. Most recently,{{when|date=March 2020}} the multinational pharmaceutical giant Sanofi –Aventis awarded Regulus with the largest microRNA partnership to date – targeting fibrosis.
Research collaborations
Patents
Regulus has more than 900 patents and patent applications, 600 of which cover the method of use, chemical modification and administration of oligonucleotides to address specific targets.{{cite web |url=http://www.regulusrx.com/pdf/Regulus_Strat_062810.pdf |title=A handful would be fine |publisher= |work=BioCentury |author=Flanagan, Michael |date=June 2010 }}
References
{{Reflist|colwidth=30em}}
External links
- [http://www.regulusrx.com Regulus Therapeutics official website]
{{Authority control}}
Category:Companies listed on the Nasdaq